Nonprofit · EIN 86-0818253
INTERNATIONAL CANCER ADVOCACY NETWORK
Tax-exempt · PHOENIX, AZ 85021
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2024 | 990 | $2,722,014 | $1,230,745 | $1,491,269 | $5,274,894 | $20,722 | $5,254,172 |
| December 31, 2023 | 990 | $1,451,316 | $1,027,905 | $423,411 | $3,781,783 | $14,196 | $3,767,587 |
Financial details: 990 for the year ended December 31, 2024
Revenue
- Contributions, gifts and grants
- $2,692,996
- Program service revenue
- $0
- Investment income
- $58,103
- Net gain from sales of assets
- -$21,850
- Net income from fundraising events
- -$29,085
- Other revenue
- -$29,085
Expenses
- Grants and similar amounts paid
- $360,000
- Compensation of officers, directors and key employees
- $190,000
- Salaries, compensation and benefits (total)
- $220,518
- Professional fundraising fees
- $0
- Legal fees
- $3,050
- Accounting fees
- $9,075
- Occupancy
- $44,486
- Program services (functional)
- $1,131,229
- Management and general (functional)
- $83,398
- Fundraising (functional)
- $16,118
Balance sheet and other
- Total assets, start of year
- $3,781,783
- Total assets, end of year
- $5,274,894
- Total liabilities, end of year
- $20,722
- Net assets, end of year
- $5,254,172
- Land, buildings and equipment
- $653,519
- Net assets without donor restrictions
- $5,254,172
- Gross receipts
- $3,081,703
- Employees
- 1
- Volunteers
- 136
- Year formed
- 1995
- State of legal domicile
- AZ
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2024, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| MARCIA K HORN JD | PRESIDENT AN Trustee or director, Officer | 90 | $190,000 | $17,571 |
| SHERRY WEINSTEIN | CHAIR-TTEES- Trustee or director, Officer | 30 | $0 | $0 |
| CATHY DALZELL | CHAIR ADIVIS Trustee or director, Officer | 15 | $0 | $0 |
| CHERYL J HINTZEN-GAINES | CHAIR-HONORA Trustee or director, Officer | 3 | $0 | $0 |
| SIDNEY M ROSEN ESQ | FOUNDING CHA Trustee or director, Officer | 10 | $0 | $0 |
| DONNA STONE | CHAIR, NATIO Trustee or director, Officer | 15 | $0 | $0 |
990 for the year ended December 31, 2023: 5 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| MARCIA K HORN JD | PRESIDENT AN Trustee or director, Officer | 90 | $172,000 | $27,531 |
| SHERRY WEINSTEIN | CHAIR-TTEES- Trustee or director, Officer | 30 | $0 | $0 |
| CATHY DALZELL | CHAIR ADIVIS Trustee or director, Officer | 10 | $0 | $0 |
| CHERYL J HINTZEN-GAINES | CHAIR-HONORA Trustee or director, Officer | 3 | $0 | $0 |
| SIDNEY M ROSEN ESQ | FOUNDING CHA Trustee or director, Officer | 10 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 27 W MORTEN AVE, PHOENIX, AZ 85021-7246
- In care of
- % MARCIA K HORN PRESIDENT CEO
- Principal officer (990 for 2024)
- MARCIA K HORN JD, 27 WEST MORTEN AVENUE, PHOENIX, AZ 85021
- Signed the 990
- MARCIA K HORN JD, PRESIDENT AND CEO
- Phone
- (602) 618-0183
- Website
- WWW.ASKICAN.ORG
- Return prepared by
- ECKELBERG & WIENSHIENK PC
Mission
ICAN'S MISSION IS TWO-FOLD: TO OPTIMIZE STAGE IV CANCER PATIENT SURVIVAL AND WORK TO ATTAIN THE HIGHEST POSSIBLE QUALITY OF LIFE. ICAN ASSISTS STAGE IV CANCER PATIENTS WITH 1) DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES; 2) REFERRALS TO ONCOLOGISTS IN ACADEMIC MEDICAL CENTERS AS WELL AS COMMUNITY PRACTICES; 3) EDUCATING PATIENTS REGARDING THE IMPERATIVE OF MOLECULAR PROFILING; 4) EXPEDITING ACCESS TO MOLECULAR PROFILING; 5) EDUCATING PATIENTS AND THEIR CARE PARTNERS REGARDING CLINICAL TRIALS AND MOLECULAR MATCHING OF THE PATIENT TO CLINICAL TRIALS; AND 6) EXPEDITING PATIENT ACCESS TO COMPASSIONATE USE/EXPANDED ACCESS PROGRAMS. ICAN IS A PAN-HEME CANCER, PAN-SOLID TUMOR, PAN-SARCOMA, AND PAN-RARE CANCER PATIENT ADVOCACY ORGANIZATION AND RESEARCH ADVOCACY ORGANIZATION. ICAN ALSO FOCUSES ON EXPANDING PATIENT ACCESS AND GALVANIZING OUR COLLABORATORS TO ASSIST UNDER-RESOURCED PATIENT COMMUNITIES IN THE US AND ABROAD WITH CUSTOMIZED INFORMATION SERVICES. ICAN ANNUALLY AWARDS R
Program accomplishments
- PATIENT NAVIGATION PROGRAMS, INCLUDING PATIENT PROGRAM SERVICES/RESEARCH ADVOCACY PROGRAMS/CANCER RESEARCH SERVICES OF WHICH 360,000 WAS AWARDED IN GRANTS TO INVESTIGATORS ASSOCIATED WITH OR COLLABORATING WITH ICAN'S INTERNATIONAL RESEARCH CONSORTIUM, INCLUDING THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, THE UNIVERSITY OF TEXAS SOUTHWESTERN, THE UNIVERSITY OF PENNSYLVANIA, DANA-FARBER CANCER INSTITUTE AND CITY OF HOPE. GRANTS WERE AWARDED FOR PROPOSALS RELATING TO MOLECULAR ALTERATIONS AND RESISTANCE MECHANISMS, DEVELOPMENT OF DRUGS WITH NEW MECHANISMS OF ACTION, DEVELOPMENT OF EARLY DETECTION ASSAYS,AND RESEARCH REGARDING LEPTOMENINGEAL DISEASE (LMD). THE 2024-2025 GRANT CYCLE WAS FUNDED BY ICAN'S SPECIAL EVENTS, INCLUDING THE ANNUAL FISTBUMP FUNDRAISER AND THE ANNUAL APPLIED UNDERWRITING GOLF TOURNAMENT AS WELL AS BY ICAN MEMORIAL AND TRIBUTE PROGRAMS. ICAN'S EXON 20 INTERNATIONAL RESEARCH CONSORTIUM CONSISTS OF TOP THORACIC RESEARCH ONCOLOGISTS AND SCIENTISTS WHO HAVE PRODUCED AN ARRAY OF TRANSFORMATIVE AND PRACTICE CHANGING JOURNAL ARTICLES THAT ARE PROPELLING THE FIELD OF ACTIONABLE MUTATIONS FORWARD. ICAN'S PATIENT SERVICES FOCUS ON HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS CANCERS, AND RARE CANCERS. OUR PATIENTS, CARE PARTNERS, AND RESEARCH ADVOCATES REVIEW CLINICAL TRIAL CONCEPTS, PROTOCOLS, AND INFORMED CONSENT FORMS. THE ORGANIZATION'S ONCOLOGY NURSING SERVICES AND ANGEL BUDDIES/MET MENTORS (PEER-TO-PEER PATIENT AND CARE PARTNER ADVISORS) ASSIST PATIENTS AND THEIR FAMILIES WITH SIDE EFFECTS MITIGATION STRATEGIES THROUGHOUT CLINICAL TRIALS AND STANDARD TREATMENT. UNDER THE ICAN NONPROFIT UMBRELLA, ICAN MANAGES THE EXON 20 GROUP (EGFR EXON 20 WARRIORS/HER2 WARRIORS), THE MET CRUSADERS, THE BIOMARKER COLLABORATIVE, THE PD-L1 AMPLIFIEDS, AND THE NRG1 ENERGIZERS.Expenses $679,792 · grants $360,000
- PATIENT, CARE PARTNER, AND CLINICIAN EDUCATION/ U.S. AND GLOBAL PATIENT ACCESS PROGRAMS-FOCUSING ON PATIENT ACCESS TO MOLECULAR TESTING AND PRECISION MEDICINE; U.S. AND GLOBAL ACCESS ISSUES RELATED TO UNDER- RESOURCED PATIENT COMMUNITIES; EARLY DETECTION (IMAGING AND MOLECULAR DIAGNOSTICS); ONGOING HEALTH INFORMATION PROJECTS FOR EXON 20 GROUP, MET CRUSADERS, BIOMARKER COLLABORATIVE, AND PAN-TUMOR ICAN PROGRAMS; AND ACCESS ISSUES REGARDING EXPANDED ACCESS/PRE-APPROVAL ACCESS/COMPASSIONATE USE PROGRAMS IN THE U.S. AND ABROAD. ICAN'S PUBLIC POLICY ADVOCACY EFFORTS WERE VIGOROUSLY PURSUED AT THE STATE AND FEDERAL LEVELS, INCLUDING ISSUES SUCH AS THE INFLATION REDUCTION ACT AND FIXING THE SMALL MOLECULE PENALTY; WEIGHING IN ON PRESCRIPTION DRUG AFFORDABILITY BOARDS; SUPPORTING PBM REFORM; SUPPORTING 340B PROGRAM REFORM; ADVOCATING FOR THE PRESERVATION OF THE BAYH-DOLE PROGRAM; SUPPORTING BIOMARKER TESTING BILLS (PASSED IN 22 STATES AND COUNTING); SUPPORTING CO-PAY ACCUMULATOR AND REBATE REFORM BILLS (ACTIVE PARTICIPANT IN THE "ALL COPAYS COUNT COALITION"), AND OPPOSING STATE-LED EFFORTS THAT IMPEDE PATIENT ACCESS TO NOVEL THERAPEUTICS, SUCH AS STEP THERAPY/FAIL- FIRST THERAPY WHERE WE HAVE VIGOROUSLY OPPOSED THOSE ANTI-PATIENT PRACTICES SINCE 2012.Expenses $225,917
- MOLECULAR PROFILING CONNECTION SERVICES/CLINICAL TRIALS MATCHING SERVICES: 1) ADVISING PATIENTS ON THE IMPORTANCE OF NEXT-GENERATION SEQUENCING AND EDUCATING THEM ABOUT THE ARRAY OF MOLECULAR PROFILING TECHNOLOGIES THAT CAN EITHER BE ACCESSED BY PATIENTS AND/OR RESEARCHERS--DNA, RNA, AND THUS MULTI-OMICS: GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, METABOLOMICS, METHYLATION, IMMUNE CELL STUDIES, AND SO FORTH; 2) REVIEWING MOLECULAR PROFILING REPORTS WITH PATIENTS AND THEIR CARE PARTNERS; 3) CONVENING AD HOC MOLECULAR TUMOR BOARDS WHERE NEEDED, WITH THE INPUT OF MEMBERS OF ICAN'S BIOMARKERS COUNCIL, PHYSICIANS COUNCIL, AND DRUG DEVELOPMENT COUNCIL; 4) EDUCATING PATIENTS ABOUT MOLECULAR TUMOR BOARDS (E.G. TARGET CANCER'S TRACK STUDY, ASCO TAPUR STUDY; ROCHE NAVIFY); AND, 5) CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON A PAN-TUMOR/PAN- HEME/PAN-RARE CANCER BASIS IF AN APPROPRIATE CLINICAL TRIAL IS A MOLECULAR MATCH. ICAN AND ITS SUPPORT GROUPS ARE ALSO ENGAGED IN THE AREAS OF DECENTRALIZING TRIALS; "JUST-IN-TIME" TRIALS; AND EXPEDITING THE TRANSFER OF PATIENTS FROM ONE CLINICAL TRIALS SITE (MID-REGIMEN) TO ANOTHER MORE CONVENIENT SITE (U.S. TO U.S. OR EU TO U.S.). ICAN, THE EXON 20 GROUP, AND THE MET CRUSADERS SPECIALIZE IN CLINICAL TRIAL ACCRUAL AND RETENTION ISSUES AS WELL AS CLINICAL TRIALS SITE SELECTION ISSUES. THE BIOMARKER COLLABORATIVE 1) CONNECTS PATIENTS TO BOTH THE APPROPRIATE SPECIFIC BIOMARKER SUPPORT GROUP AND THE RELEVANT GENERAL ORGANIZATIONS THAT COVER THE PATIENT'S SPECIFIC CANCER TYPE; AND 2) EDUCATES PATIENTS ABOUT THEIR DRIVER MUTATION, AMPLIFICATION OR FUSION (IF IDENTIFIED BY THE RELEVANT LABORATORY'S REPORT) AS WELL AS THEIR GENE CO-ALTERATIONS. ICAN AND ITS SUPPORT ORGANIZATIONS EACH STRESS THE IMPORTANCE OF MULTI-STAKEHOLDER COLLABORATIONS WITH RESEARCH ADVOCATES, PATIENT ADVOCATES, COMMUNITY ADVOCATES, CLINICIANS, AND SCIENTISTS.Expenses $248,520
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | Not on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 86-0818253
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 1996
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Philanthropy, voluntarism and grantmaking foundations (T22)
- Assets (IRS master file)
- $5,274,894
- Income (IRS master file)
- $3,081,703
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2024 | $2,722,014 | $1,230,745 | $5,274,894 | XML |
| 990 | December 2023 | $1,451,316 | $1,027,905 | $3,781,783 | XML |
| 990 | December 2022 | $1,357,826 | $915,666 | $3,351,569 | IRS |
| 990 | December 2021 | – | – | – | IRS |
| 990 | December 2020 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 86-0818253).
Questions about INTERNATIONAL CANCER ADVOCACY NETWORK
- What is the EIN of INTERNATIONAL CANCER ADVOCACY NETWORK?
- The employer identification number (EIN) of INTERNATIONAL CANCER ADVOCACY NETWORK is 86-0818253.
- Is INTERNATIONAL CANCER ADVOCACY NETWORK tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1996.
- Are donations to INTERNATIONAL CANCER ADVOCACY NETWORK tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does INTERNATIONAL CANCER ADVOCACY NETWORK file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of INTERNATIONAL CANCER ADVOCACY NETWORK due?
- The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did INTERNATIONAL CANCER ADVOCACY NETWORK last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2024.
- Who is the principal officer of INTERNATIONAL CANCER ADVOCACY NETWORK?
- The 990 for the year ended December 31, 2024 names MARCIA K HORN JD.
- Who are the officers and directors of INTERNATIONAL CANCER ADVOCACY NETWORK?
- The 990 for the year ended December 31, 2024 lists 6 people; 1 received compensation from the organization, the highest $190,000 (MARCIA K HORN JD, PRESIDENT AN).
- How much revenue does INTERNATIONAL CANCER ADVOCACY NETWORK have?
- On its 990 for the year ended December 31, 2024 it reported revenue of $2,722,014, expenses of $1,230,745 and total assets of $5,274,894 at year end.
Other nonprofits in PHOENIX
- ARIZONA COMMUNITY FOUNDATION EIN 86-0348306 · last filed 990 for 2025
- FH ASSOCIATION EIN 20-8424918 · last filed 990 for 2025
- VALLEY OF THE SUN UNITED WAY EIN 86-0104419 · last filed 990 for 2025
- VIRGINIA G PIPER CHARITABLE TRUST 08-11-95 EIN 86-6247076 · last filed 990-PF for 2025
- MORENO FAMILY FOUNDATION EIN 86-0918198 · last filed 990-PF for 2024
- KEMPER & ETHEL MARLEY FOUNDATION EIN 86-0653091 · last filed 990-PF for 2024
- PIVOTAL FOUNDATION EIN 20-3959093 · last filed 990-PF for 2024
- SPROUTS HEALTHY COMMUNITIES FOUNDATION EIN 47-2975827 · last filed 990 for 2024
All nonprofits in PHOENIX · Arizona · Philanthropy, voluntarism and grantmaking foundations